These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 38608056

  • 1. A challenging issue in COVID-19 infection: The relationship between PA1-1 and TAFI levels in patients with coagulation disorder: A retrospective and observational study.
    Altin N, Tiğlioğlu P, Ulusoy TU, Aydin FN, Kar İ, Karakoc B, Utebey G.
    Medicine (Baltimore); 2024 Apr 12; 103(15):e37802. PubMed ID: 38608056
    [Abstract] [Full Text] [Related]

  • 2. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 3. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 06; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 4. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug 06; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 5. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
    Coleman JR, Moore EE, Kelher MR, Jones K, Cohen MJ, Banerjee A, Silliman CC.
    J Trauma Acute Care Surg; 2023 Jun 01; 94(6):857-862. PubMed ID: 36787438
    [Abstract] [Full Text] [Related]

  • 6. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 01; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 7. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 8. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov 08; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 9. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 08; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 10. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 08; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 11. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 12. Changes in the Fibrinolytic System of Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2.
    Abudouleh E, Alhamlan F, Al-Qahtani AA, Bohol MF, Al Hazzani A, Khorfan K, Alkaff M, Owaidah T, Al-Qahtani AA.
    J Clin Med; 2023 Aug 10; 12(16):. PubMed ID: 37629265
    [Abstract] [Full Text] [Related]

  • 13. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep 10; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 14. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 10; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 15. Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
    Wada H, Nobori T, Watanabe R, Shiku H, Sakuragawa N.
    Turk J Haematol; 2002 Jun 05; 19(2):235-7. PubMed ID: 27264764
    [Abstract] [Full Text] [Related]

  • 16. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 05; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 17. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 05; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolysis parameters in Sudanese women with severe preeclampsia.
    Elzein HO, Muddathir AR, Rida M, Rayis DA, Elhassan EM, Adam I.
    Hypertens Pregnancy; 2016 Nov 05; 35(4):559-564. PubMed ID: 27598010
    [Abstract] [Full Text] [Related]

  • 19. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
    Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A.
    J Thromb Haemost; 2012 Dec 05; 10(12):2555-62. PubMed ID: 23083123
    [Abstract] [Full Text] [Related]

  • 20. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 05; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.